MVIR-B.ST Stock - Medivir AB (publ)
Unlock GoAI Insights for MVIR-B.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $4.41M | $25.54M | $13.95M | $8.72M | $23.86M |
| Gross Profit | $-64,670,000 | $-47,739,000 | $-38,984,000 | $-82,339,000 | $23.86M |
| Gross Margin | -1467.1% | -186.9% | -279.5% | -943.8% | 100.0% |
| Operating Income | $-87,354,000 | $-62,118,000 | $-42,900,000 | $-125,979,000 | $-351,030,000 |
| Net Income | $-89,221,000 | $-63,125,000 | $-41,047,000 | $-123,440,000 | $-350,314,000 |
| Net Margin | -2024.1% | -247.2% | -294.3% | -1414.9% | -1468.0% |
| EPS | $-1.60 | $-1.20 | $-1.39 | $-4.17 | $-12.01 |
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Visit WebsiteEarnings History & Surprises
MVIR-B.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Apr 25, 2024 | — | — | — | — |
Q1 2024 | Feb 13, 2024 | — | — | — | — |
Q4 2023 | Nov 3, 2023 | — | — | — | — |
Q3 2023 | Aug 18, 2023 | $-0.34 | $-0.48 | -40.4% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2023 | Feb 15, 2023 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.49 | $-0.27 | +44.9% | ✓ BEAT |
Q3 2022 | Aug 19, 2022 | $-0.50 | $-0.42 | +16.0% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $-0.37 | $-0.59 | -59.5% | ✗ MISS |
Q1 2022 | Feb 15, 2022 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.18 | $-0.26 | -44.4% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | $-0.45 | $-0.35 | +22.2% | ✓ BEAT |
Q2 2021 | Apr 28, 2021 | $-0.55 | $-0.18 | +67.3% | ✓ BEAT |
Q1 2021 | Feb 26, 2021 | $-1.03 | $-0.46 | +55.3% | ✓ BEAT |
Q4 2020 | Nov 10, 2020 | $-0.59 | $0.16 | +127.1% | ✓ BEAT |
Q3 2020 | Aug 20, 2020 | $-0.93 | $-0.43 | +53.8% | ✓ BEAT |
Q2 2020 | May 5, 2020 | $-1.02 | $-0.79 | +22.5% | ✓ BEAT |
Q1 2020 | Feb 13, 2020 | $-0.75 | $-1.08 | -44.0% | ✗ MISS |
Q4 2019 | Nov 27, 2019 | $-0.88 | $-0.78 | +11.4% | ✓ BEAT |
Q3 2019 | Aug 28, 2019 | $-2.01 | $-0.42 | +79.1% | ✓ BEAT |
Latest News
Frequently Asked Questions about MVIR-B.ST
What is MVIR-B.ST's current stock price?
What is the analyst price target for MVIR-B.ST?
What sector is Medivir AB (publ) in?
What is MVIR-B.ST's market cap?
Does MVIR-B.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MVIR-B.ST for comparison